Trial Profile
A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2022
Price :
$35
*
At a glance
- Drugs IONIS-HBV-LRx (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline KK; GSK
- 12 Dec 2022 Results (n=64)assessing Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region published in the Antimicrobial Agents and Chemotherapy
- 14 Jun 2022 Results published in the Journal of Hepatology
- 24 Jan 2020 Status changed from active, no longer recruiting to completed.